Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection

Robert L. Murphy*, Roy M. Gulick, Victor DeGruttola, Richard T. D'Aquila, Joseph J. Eron, Jean Pierre Sommadossi, Judith S. Currier, Laura Smeaton, Ian Frank, Angela M. Caliendo, John G. Gerber, Roger Tung, Daniel R. Kuritzkes

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

78 Scopus citations

Abstract

Amprenavir is a human immunodeficiency virus (HIV) protease inhibitor with a favorable pharmacokinetic profile and good in vitro activity. Ninety- two lamivudine- and protease inhibitor-naive individuals with ≥50 CD4 cells/mm3 and ≥5000 HIV RNA copies/mL were assigned amprenavir (1200 mg) alone or with zidovudine (300 mg) plus lamivudine (150 mg), all given every 12 h. After a median follow-up of 88 days, the findings of a planned interim review resulted in termination of the amprenavir monotherapy arm. Among 85 subjects with confirmed plasma HIV RNA determination, 15 of 42 monotherapy versus 1 of 43 tripletherapy subjects had an HIV RNA increase above baseline or 1 log10 above nadir (P = .0001). For subjects taking triple therapy at 24 weeks, the median decrease in HIV RNA was 2.04 log10 copies/mL, and 17 (63%) of 27 evaluable subjects had <500 HIV RNA copies/mL. Treatment with amprenavir, zidovudine, and lamivudine together reduced the levels of HIV RNA significantly more than did amprenavir monotherapy.

Original languageEnglish (US)
Pages (from-to)808-816
Number of pages9
JournalJournal of Infectious Diseases
Volume179
Issue number4
DOIs
StatePublished - 1999

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection'. Together they form a unique fingerprint.

Cite this